TREND-MICRO-INCORPORATED
Trend Micro Incorporated (TYO: 4704 ; TSE: 4704 ), a global leader in cybersecurity solutions, today released survey results that show how remote workers address cybersecurity. Nearly three quarters (72%) of remote workers say they are more conscious of their organisation’s cybersecurity policies since lockdown began, but many are breaking the rules anyway due to limited understanding or resource constraints.
Trend Micro’s Head in the Clouds study is distilled from interviews with 13,200 remote workers across 27 countries on their attitudes towards corporate cybersecurity and IT policies. It reveals that there has never been a better time for companies to take advantage of heightened employee cybersecurity awareness. The survey reveals that the approach businesses take to training is critical to ensure secure practices are being followed.
The results indicate a high level of security awareness, with 85% of respondents claiming they take instructions from their IT team seriously, and 81% agree that cybersecurity within their organisation is partly their responsibility. Additionally, 64% acknowledge that using non-work applications on a corporate device is a security risk.
However, just because most people understand the risks does not mean they stick to the rules.
For example:
- 56% of employees admit to using a non-work application on a corporate device, and 66% of them have actually uploaded corporate data to that application.
- 80% of respondents confess to using their work laptop for personal browsing, and only 36% of them fully restrict the sites they visit.
- 39% of respondents say they often or always access corporate data from a personal device – almost certainly breaking corporate security policy.
- 8% of respondents admit to watching / accessing porn on their work laptop, and 7% access the dark web.
Productivity still wins out over protection for many users. A third of respondents (34%) agree that they do not give much thought to whether the apps they use are sanctioned by IT or not, as they just want the job done. Additionally, 29% think they can get away with using a non-work application, as the solutions provided by their company are ‘nonsense.’
Dr Linda K. Kaye, Cyberpsychology Academic at Edge Hill University explains: “There are a great number of individual differences across the workforce. This can include individual employee’s values, accountability within their organisation, as well as aspects of their personality, all of which are important factors which drive people’s behaviours. To develop more effective cybersecurity training and practices, more attention should be paid to these factors. This, in turn, can help organisations adopt more tailored or bespoke cybersecurity training with their employees, which may be more effective.”
“In today’s interconnected world, unashamedly ignoring cybersecurity guidance is no longer a viable option for employees,” said Bharat Mistry, Principal Security Strategist, Trend Micro. “It’s encouraging to see that so many take the advice from their corporate IT team seriously. Having said that, there are individuals who are either blissfully ignorant or worse still who think cybersecurity is not applicable them and will regularly flouter the rules. Hence having a one size fits all security awareness programme is a non-starter as diligent employees often end up being penalised. A tailored training programme designed to cater for employees may be more effective.”
The Head in the Clouds study looks into the psychology of people’s behaviour in terms of cybersecurity, including their attitudes towards risk. It presents several common information security “personas” with the aim of helping organisations tailor their cybersecurity strategy in the right way for the right employee.
About Trend Micro
Trend Micro Incorporated, a global leader in cybersecurity solutions, helps to make the world safe for exchanging digital information. Our innovative solutions for consumers, businesses, and governments provide layered security for data centers, cloud environments, networks, and endpoints. All our products work together to seamlessly share threat intelligence and provide a connected threat defense with centralized visibility and control, enabling better, faster protection. With more than 6,000 employees in over 50 countries and the world’s most advanced global threat intelligence, Trend Micro secures your connected world. For more information, visit www.trendmicro.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005158/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
